Gemfibrozil

Drug Usage Statistics, United States, 2004 - 2014

Number of Prescriptions Over Time (2004 - 2014)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2004 103 -
2005 113  10
2006 96  17
2007 114  18
2008 133  19
2009 108  25
Year Rank Change
2010 105  3
2011 120  15
2012 120 0
2013 159  39
2014 148  11

Patient Out-Of-Pocket Cost Over Time (2004 - 2014)

"Out-of-pocket" cost refers to the payment made by the patient (either cash price or the copay amount). This value does not include reimbursement from a third party payer (eg, Medicare or private insurance) and does not represent the total drug cost.

Usage Statistics of Related Drugs

Drug Name Total Prescriptions (2014)
Fenofibrate 16,184,872
Pioglitazone Hydrochloride 6,528,321
Gemfibrozil (this drug) 4,660,295

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Lopid
Generic Drug Synonyms and Salts
  • Gemfibrozil

FDA Approval Information

Established Pharmacologic Class (EPC): Peroxisome Proliferator Receptor alpha Agonist
Initial FDA approval date: Prior to January 1, 1982
First FDA applicant: Pfizer Pharmaceuticals Ltd
First dosage form: Capsule (oral)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2004-2014. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 17.0. Read more about the ClinCalc DrugStats database.

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

Gorillas can't learn drug therapy ... but you can. The Top 250 Drugs by ClinCalc Academy
©2017 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Mar 4, 2017
Back to Top
Top